Germany vindicates Pfizer's Vyndaqel
This article was originally published in Scrip
Executive Summary
Pfizer's orphan drug Vyndaqel (tafamidis meglumine) for transthyretin familial amyloid polyneuropathy (TTR-FAP) offers additional benefit, as proven by the drug's marketing approval for treating an orphan disease, says IQWiG, Germany's Institute for Quality and Efficiency in Healthcare.